Skip to content

Stress Testing and Cardiac Magnetic Resonance

Stress Testing and Cardiac Magnetic Resonance

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00871260
Enrollment
20
Registered
2009-03-30
Start date
2009-04-30
Completion date
2014-06-04
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Disease

Keywords

Coronary Disease, Stress Testing, Lexiscan (regadenoson), Cardiac Magnetic Resonance Imaging

Brief summary

The purpose of this study is to better define the role of a comprehensive stress MRI (which includes myocardial perfusion imaging, optimized coronary imaging, and myocardial scar imaging) in medical practice and in patient health management. Information gathered from the healthy volunteers that participate in this study will be compared to information from the coronary artery disease patients in this study in order to help further our understanding.

Detailed description

Coronary artery disease is a major cause of morbidity and mortality in the United States. Currently, the presence of physiologically significant coronary disease is most commonly diagnosed using non-invasive imaging tests such as a nuclear stress test or an echo stress test. Unfortunately, nuclear stress tests require the use of ionizing radiation and have a limited spatial resolution. On the other hand, echo stress tests are dependent of adequate imaging windows. Adenosine stress testing combined with cardiac magnetic resonance (CMR) is a rapidly evolving technique for diagnosing significant coronary disease. It does not use ionizing radiation and has excellent image quality. In a recent meta-analysis of 14 studies with a total of 1,183 patients, the sensitivity and specificity of stress CMR for detecting significant coronary disease was 91% and 81%. Additionally, 2 studies have shown that patients with a normal stress CMR study have a \<1% risk of having a cardiovascular event during the ensuing year. Another important advantage to stress CMR is the ability to fully quantify myocardial blood flow which may improve the diagnostic accuracy of stress CMR. In addition to perfusion imaging, CMR can directly visualize the coronary arteries, detect extremely small myocardial infarctions, and precisely measure the left ventricular function. Although adenosine stress CMR is a rapidly maturing test, several important challenges exist. First, many patients find it difficult to tolerate the common side effects of adenosine in the confined space of the MRI scanner. Secondly, many patients under the influence of adenosine and its side effects cannot adequately hold their breath during image acquisition making image interpretation more difficult and quantitative analysis very time consuming. Finally, because adenosine must be continuously infused during a contrast-enhanced stress CMR, 2 separate intravenous (I.V.) catheters are needed. Most of the undesirable effects of adenosine are mediated through the adenosine A(2B) and A(3) receptors; where as, its desired vasodilator effects are mediated through the A(2A) receptor. The FDA recently approved an adenosine A(2A) receptor specific stress testing agent called regadenoson which is administered as a 10 second bolus and has an improved side effect and safety profile when compared to adenosine. With its improved tolerability and ease of use, regadenoson is a more ideal stress testing agent to use with CMR. The purpose of this study is to determine whether a comprehensive regadenoson stress cardiac magnetic resonance study which includes myocardial perfusion imaging, optimized coronary imaging, and myocardial scar imaging provides incremental prognostic information over a clinical evaluation that includes nuclear stress testing.

Interventions

DRUGregadenoson

Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.

Sponsors

Astellas Pharma Inc
CollaboratorINDUSTRY
University of Chicago
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Suspected coronary artery disease * Symptoms of possible coronary artery disease

Exclusion criteria

* Acute ST-elevation myocardial infarction * Second or third degree AV block * Severe Renal Disease (Glomerular Filtration Rate (GFR) \<30cc/min or hemodialysis) * Contra-indications to MRI (i.e. Implantable Cardioverter Defibrillator (ICD), pacemaker, aneurysm clip, etc) * Hemodynamic instability * Inability to provide informed consent * Severe claustrophobia * Pregnancy * Age \<18 years

Design outcomes

Primary

MeasureTime frameDescription
Major Adverse Cardiovascular Events3 yearsMajor adverse cardiovascular events, such as death, myocardial infarction, unstable angina, congestive heart failure, or cerebral vascular accident.

Secondary

MeasureTime frameDescription
Relationship Between SPECT and CMR Results of Myocardial Perfusion Imaging1 yearRelationship between SPECT and CMR results of myocardial perfusion imaging for 1 Year
Optimization of Coronary Imaging Using CMR1 yearOptimization of coronary imaging using CMR for 1 Year

Countries

United States

Participant flow

Participants by arm

ArmCount
Healthy Patients
Due to low enrollment, twenty healthy subjects underwent CMR perfusion imaging during resting conditions, during regadenoson-induced hyperemia (0.4 mg), and after 15 min of recovery. All analyzes were based upon current enrollment.
20
Total20

Baseline characteristics

CharacteristicHealthy Patients
Age, Continuous32 years
STANDARD_DEVIATION 13
Race/Ethnicity, Customized
Caucasian
12 Participants
Race/Ethnicity, Customized
Not Caucasian
8 Participants
Sex: Female, Male
Female
12 Participants
Sex: Female, Male
Male
8 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
9 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Major Adverse Cardiovascular Events

Major adverse cardiovascular events, such as death, myocardial infarction, unstable angina, congestive heart failure, or cerebral vascular accident.

Time frame: 3 years

Population: All efforts were taken to gather all possible data but none were obtained for this Outcome Measure.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Healthy PatientsMajor Adverse Cardiovascular Events0 Participants
Secondary

Optimization of Coronary Imaging Using CMR

Optimization of coronary imaging using CMR for 1 Year

Time frame: 1 year

Population: Coronary imaging were unable to be performed. All efforts were taken to gather all possible data but none were obtained for this Outcome Measure.

Secondary

Relationship Between SPECT and CMR Results of Myocardial Perfusion Imaging

Relationship between SPECT and CMR results of myocardial perfusion imaging for 1 Year

Time frame: 1 year

Population: Coronary imaging pulse sequences were unable to be performed. All efforts were taken to gather all possible data but none were obtained for this Outcome Measure.

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026